727993-77-3

Upstream product

• 727993-76-2 5-methoxy-2,3-dihydro-1H-pyrrolo[2,3-c]pyridine-7-carbonitrile 
• 100-58-3 phenylmagnesium bromide 
• 412030-10-5 5-methoxy-2,3-dihydro-1H-pyrrolo[2,3-c]pyridine 
• 727993-73-9 2-{5-[(tert-butoxycarbonyl)amino]-2-methoxypyridin-4-yl}ethyl methanesulfonate 
• 727993-72-8 tert-butyl [4-(2-hydroxyethyl)-6-methoxypyridin-3-yl]carbamate 
• 727993-74-0 tert-butyl 5-methoxy-2,3-dihydro-1H-pyrrolo[2,3-c]pyridine-1-carboxylate 
• 727993-75-1 7-bromo-5-methoxy-2,3-dihydro-1H-pyrrolo[2,3-c]pyridine 
• 6628-77-9 6-methoxy-pyridin-3-ylamine 

Downstream Products

• 727993-81-9 N-(4-methoxy-9-oxo-6-phenyl-1,2,8,9-tetrahydro-5,7,9a-triaza-benzo[cd]azulen-8-yl)-nicotinamide 
• 727993-79-5 8-azido-4-methoxy-6-phenyl-1,2-dihydro-8H-5,7,9a-triaza-benzo [cd] azulen-9-one 
• 727993-80-8 8-Amino-4-methoxy-6-phenyl-1,2-dihydro-8H-5,7,9a-triaza-benzo[cd]azulen-9-one 
• 727993-78-4 4-methoxy-6-phenyl-1,2-dihydro-8H 5,7,9a-triaza-benzo[cd]azulen-9-one 

Relevant academic research and scientific papers

Preparation of azaindolines and benzoyl substituted azaindolines: Precursors of triazabenzo[cd]azulen-9-one PDE4 inhibitors

The syntheses of various substituted azaindolines are described. Azaindolines were identified as potential key intermediates towards new PDE4 inhibitors.

Azabenzodiazepines as pde4 inhibitors

Compounds of formula (I): characterized in that:R1 represents a group selected from hydrogen atom, methyl, methoxy, hydroxy, amino, dimethylamino, acetamido, pyrrolidin-1-yl, and hydroxymethyl;R2 represent a group selected from phenyl, pyridyl, pyrimidyl, quinolyl, isoquinolyl, indolyl, pyrolyl, [1,2,3]-triazolyl, benzo[c]isoxazolyl, thienyl, pyrazolyl, isothiazolyl, imidazolyl, benzofuranyl, pyrazolo[5,1-c][1,2,4]triazyl each of these groups being optionally substituted from 1 to 3 groups, identical or different independently of each other, selected from halogen, trifluoromethyl, (C1-C4)alkyl, (C1-C4)alkoxy, hydroxy, amino, acetamido, tert-butyloxycarbonylamino, cycloalkylcarbonylamino, sulfonamide, nitro, acetylmethoxy, cyclopentyloxy; optionally, their optical isomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and their use as active ingredient in pharmaceutical composition useful for treating diseases involving therapy by inhibition of PDE4.